Tag Archives: funding

Applied Research and Development Awards Announced

Posted on by
Reply

The Center for Biotechnology has announced the recipients of the 2016-2017 Applied Research & Development (ARAD) awards. The ARAD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community and the later-stage commercial development interests of the bioscience industry.

The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy. The projects funded include:

  • ICU Temporary Pacemaker – Dr. Wei Lin and Avery Biomedical Device, Inc.
  • Novel Synergistic and Pleiotropic Skin Brightening Agents – Dr. Sanford Simon and Biocogent, LLC
  • Continued In vivo Testing of Vaccine Candidates – Dr. Eckard Wimmer and Cogadenix, Inc.
  • Advanced Fistula-in-Ano Treatment Device – Dr. Tom Zimmerman and Pepper5, Inc.
  • Development of Nanoemulsion-PUFA-taxoids as Tumor-Targeted Chemotherapeutics – Dr. Iwao Ojima and TargaGenix, Inc.
  • Initial Pre-Clinical Safety Assessment of TRB-N0224 – Dr. Lorne Golub and Traverse Biosciences, Inc.
  • Evaluation of a Continuous Visible Light Disinfection System’s Ability to Reduce Bioburden and Subsequently the Incidence of Infections and Colonizations in an Active Patient Area – Dr. Annie Rohan and Vital Vio, Inc.

More information about the Applied Research & Development (ARAD) program, as well as all Center for Biotechnology Technology Development programs can be found here.

Long Island Bioscience Hub Welcomes Feinstein Institute

Posted on by
Reply

Stony Brook University-led initiative to accelerate commercialization of biomedical discoveries

STONY BROOK, AND MANHASSET, N.Y. – April 21, 2016 – The Center for Biotechnology at Stony Brook University and the Feinstein Institute for Medical Research, the research arm of Northwell Health, announced that the Feinstein Institute will be joining the Long Island Bioscience Hub (LIBH).

Established with a National Institutes of Health grant in 2015, Stony Brook’s Center for Biotechnology is the lead administrative institution for the LIBH, an NIH-designated Research Evaluation and Commercialization Hub (REACH). It is one of three such Hubs in the country, the mission of which is to accelerate the translation of biomedical discoveries into new drugs, devices, and diagnostics to enhance health and improve patient care. The Feinstein Institute joins LIBH members Stony Brook University, Brookhaven National Laboratory and Cold Spring Harbor Laboratory. The addition of the Feinstein Institute fulfills one of the Hub’s goals of coordinating comprehensive technology commercialization efforts across all four major bioscience research institutions on Long Island.

“We look forward to working with the Feinstein Institute, and their involvement in the Long Island Bioscience Hub further enriches the region’s burgeoning innovation economy and entrepreneurial ecosystem,” said Clinton Rubin, PhD, Director of the Center for Biotechnology. “The Feinstein Institute is a world leader in multiple areas of biomedical research, and their expertise will complement the groundbreaking work being done at Stony Brook, Brookhaven Lab, and Cold Spring Harbor.”

“The Feinstein Institute’s focus is on advancing science, treating disease, and bringing healthcare innovations to patients,” stated Dr. Kevin Tracey, President and Chief Executive Officer of the Feinstein Institute. “Our partnership in the Long Island Bioscience Hub will help ensure that scientific breakthroughs emerging from our research enterprise progress into the commercial sector where they can ultimately impact patient care. We see the Long Island Bioscience Hub as a great opportunity to accomplish our mission.”

The LIBH is connected to a network of National Institutes of Health-designated “proof of concept” centers that include the three REACH centers and three additional National Centers for Accelerated Innovation. Collectively, they are developing best practices for the commercialization of academic innovations. The Hubs & Centers also have access to resources at the federal level including the US Patent & Trademark Office, Food & Drug Administration, and Centers for Medicare & Medicaid Services to provide guidance at the earliest stages of technology development.

The LIBH will provide funding for feasibility and proof of concept studies at the four Long Island partner institutions, and coordinate access to expertise in areas required for early stage technology development, including scientific, regulatory, business, legal, and project management. The Hub will also facilitate introductions to strategic industry partners and early stage investors.  The LIBH announced its first round of technology development awards in December 2015, committing approximately $900,000 to thirteen projects. The second round of funded projects is expected to be announced in April 2016.

In addition to the Long Island Bioscience Hub’s institutional partners, support for the initiative has been provided by the Research Foundation of SUNY and Empire State Development. Total investment in the Hub over the next three years exceeds $8 million.

Download a PDF of the press release here.

 

 

 

 

Long Island Bioscience Hub Announces Funded Projects

Posted on by
Reply

Accelerating Biomedical Discoveries for Commercialization

STONY BROOK, N.Y. – December 7, 2015 – The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced today the recipients of the first technology development grants awarded by the Hub. Thirteen awards totaling $900,000 were granted to applicants from Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory.

The LIBH technology development grants are a multi-tiered funding initiative aimed at collectively contributing to a pipeline of commercially promising biomedical technology in the region. The three funding initiatives include Feasibility, Proof of Concept and Commercialization awards.

Feasibility awards are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications of an existing technology.  Proof of Concept Awards provide targeted, milestone driven support for proof of concept research, development, testing, and analysis of existing intellectual property. The final tier, Commercialization Awards, provide targeted, milestone-driven support for a subset of projects with existing intellectual property where additional investment will clearly advance the technology to a major value inflection point for commercialization.

The grants awarded this cycle will support technologies developed across multiple disciplines including pharmacology, biomedical engineering, chemistry, and microbiology. Among the award recipients were two post-doctoral researchers. Of the thirteen grants awarded, eight were Feasibility awards and five were Proof of Concept Awards. The recipients of this round of awards are:

Feasibility awards

  • Targeting Pathogenic Viral Infections with First-In-Class Viral Budding Inhibitors – Dr. Carol Carter
  • Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer – Dr. Michael Frohman
  • Novel miR-129 Based Therapeutics for Colon Cancer – Dr. Jingfang Ju
  • Fast Hybrid Approach For Determination of Structure of Therapeutic Protein Complexes – Dr. Dima Kosakov
  • Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs – Dr. Gabriel Pagnotti
  • Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration – Dr. Yixian Qin
  • LDL as Biomarker for Childhood Tuberculosis (TB) – Dr. Xinxin Yang

Proof of Concept awards

  • A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology – Dr. Marcous Abboud
  • Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams – Dr. Avraham Dilmanian
  • NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight (TOF) Positron Emission Tomography (PET) – Dr. Amirhossein Goldan
  • Azasteroids for Combination Anti-TB Therapy – Dr. Nicole Sampson
  • A Novel Glioblastoma Drug – Oncolytic Virus PV1-Mono-Cre – Dr. Eckard Wimmer

​“We are excited to see such a robust and diverse portfolio of early stage technologies supported through the LIBH and NIH-REACH consortium,” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “We are hopeful that this investment by the federal and state government, as well as SBU, CSHL and BNL, will foster and accelerate the translation of these technologies from the bench to the bed side, and help attract further investment from the industrial and financial sectors.”

The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

Commercialization Workshop for Life Sciences

Posted on by
Reply

Are you interested in learning about the skills needed to commercialize an innovation? Do you have an innovation that you are looking to bring out of the lab? Are you looking for funding to aide commercialization efforts? Attend the LIBH Commercialization Workshop.

The Long Island Bioscience Hub (LIBH) is hosting a Life Science focused Mini-Boot Camp- a one day rapid fire workshop that will provide practical tools used in commercialization as well as strategies to enhance applications for LIBH grant funding.

Thursday, October 29, 2015

8:30a-3:00pLong Island High Technology Incubator

25 Health Sciences Drive, Stony Brook, NY 11794

Who Should Attend: Faculty, Physicians, Fellows, Post Docs, Grad Students

Topics Include: Intellectual Property, Business Models, Market Needs & Size, Competitive Landscape, Regulatory Pathways

This is a free event but interested participants are asked to RSVP via email to Tiffany Tsui, PhD: tiffany.tsui@stonybrook.edu

 

Center for Biotechnology Redesignated by New York State: ‘Unique Time of Change and Growth’

Posted on by
Reply

Independently documented economic impact: $1.2 Billion

Jobs created: 1,125

New corporate revenues: $812 Million

Supported additional funding: $238 Million

Center for Biotechnology documented economic impact over recent fifteen-year period

Perhaps it is numbers like these which best illustrate the success CFB has had on the biotechnology industry and economy.

And perhaps they contributed to the redesignation of the CFB as a Center for Advanced Technology for ten years by the New York State Foundation for Science, Technology and Innovation (NYSTAR) as a Center for Advanced Technology (CAT).

The New York State redesignation recognizes the impact of the CFB over 30 years driving innovation toward commercial goals and resulting in accelerated product development cycles “from bench to boardroom to bedside.” It recognizes the key role played by the CFB in facilitating a regional bioscience innovation ecosystem, collaborating with Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory.

The redesignation by New York State validates all of the work we have done over the last 10-year period to create the foundation for exponential growth. We would not have secured the National Institutes of Health REACH award without it, says Clint Rubin, Director of the Center for Biotechnology.”The REACH designation represents an $8.1M investment in technology development, commercialization, and new company formation. Visionary’s like New York State Senator Kenneth La Valle deserve the credit. They recognized thirty years ago that universities represented a largely untapped pool of innovation and economic potential.

Strikingly, it validates and provides the foundation for the new Long Island Bioscience Hub (LIBH), a CFB-led initiative to formally bring these institutions together to foster technology development, commercialization, and new company formation. The LIBH is a bold step made possible by a partnership with the National Institute of Health REACH initiative (Research Evaluation and Commercialization Hub). The NIH award places the CFB in the national spotlight along with other elite institutions. (Read more on the NIH REACH award here)

“This redesignation occurs in an interesting and changing environment, where varying elements in the regional, state, and national biotech ecosystem are aligning. There is a confluence of events and issues that are creating a unique opportunity to build the biotech economy in the region and across the State.” Commented Diane Fabel, Director of Operations, CFB. “We have learned a lot about the process of moving academic innovation into the commercial sector over time. And there have been such tremendous scientific advances recently that represent new commercial opportunities and life saving technologies. There is still much to learn and do, and it is an incredibly exciting time to be doing it.